Title : Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4).

Pub. Date : 2015 Aug 27

PMID : 26313445






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 DCV-treated patients with undetectable HCV RNA at weeks 4 and 12 (eRVR) received 24 weeks of DCV plus PEG-IFN/RBV; those without eRVR received an additional 24 weeks of PEG-IFN/RBV. daclatasvir endogenous retrovirus group 3 member 1, envelope Homo sapiens
2 DCV-treated patients with undetectable HCV RNA at weeks 4 and 12 (eRVR) received 24 weeks of DCV plus PEG-IFN/RBV; those without eRVR received an additional 24 weeks of PEG-IFN/RBV. daclatasvir endogenous retrovirus group 3 member 1, envelope Homo sapiens